TY - JOUR
T1 - A synthetic-lethality RNAi screen reveals an ERK-mTOR cotargeting pro-apoptotic switch in PIK3CA+ oral cancers
AU - Yamaguchi, Kosuke
AU - Iglesias-Bartolomé, Ramiro
AU - Wang, Zhiyong
AU - Callejas-Valera, Juan Luis
AU - Amornphimoltham, Panomwat
AU - Molinolo, Alfredo A.
AU - Cohen, Ezra E.
AU - Califano, Joseph A.
AU - Lippman, Scott M.
AU - Luo, Ji
AU - Silvio Gutkind, J.
PY - 2016
Y1 - 2016
N2 - mTOR inhibition has emerged as a promising strategy for head and neck squamous cell carcinomas (HNSCC) treatment. However, most targeted therapies ultimately develop resistance due to the activation of adaptive survival signaling mechanisms limiting the activity of targeted agents. Thus, co-targeting key adaptive mechanisms may enable more effective cancer cell killing. Here, we performed a synthetic lethality screen using shRNA libraries to identify druggable candidates for combinatorial signal inhibition. We found that the ERK pathway was the most highly represented. Combination of rapamycin with trametinib, a MEK1/2 inhibitor, demonstrated strong synergism in HNSCC-derived cells in vitro and in vivo, including HNSCC cells expressing the HRAS and PIK3CA oncogenes. Interestingly, cleaved caspase-3 was potently induced by the combination therapy in PIK3CA+ cells in vitro and tumor xenografts. Moreover, ectopic expression of PIK3CA mutations into PIK3CA- HNSCC cells sensitized them to the pro-apoptotic activity of the combination therapy. These findings indicate that co-targeting the mTOR/ERK pathways may provide a suitable precision strategy for HNSCC treatment. Moreover, PIK3CA+ HNSCC are particularly prone to undergo apoptosis after mTOR and ERK inhibition, thereby providing a potential biomarker of predictive value for the selection of patients that may benefit from this combination therapy.
AB - mTOR inhibition has emerged as a promising strategy for head and neck squamous cell carcinomas (HNSCC) treatment. However, most targeted therapies ultimately develop resistance due to the activation of adaptive survival signaling mechanisms limiting the activity of targeted agents. Thus, co-targeting key adaptive mechanisms may enable more effective cancer cell killing. Here, we performed a synthetic lethality screen using shRNA libraries to identify druggable candidates for combinatorial signal inhibition. We found that the ERK pathway was the most highly represented. Combination of rapamycin with trametinib, a MEK1/2 inhibitor, demonstrated strong synergism in HNSCC-derived cells in vitro and in vivo, including HNSCC cells expressing the HRAS and PIK3CA oncogenes. Interestingly, cleaved caspase-3 was potently induced by the combination therapy in PIK3CA+ cells in vitro and tumor xenografts. Moreover, ectopic expression of PIK3CA mutations into PIK3CA- HNSCC cells sensitized them to the pro-apoptotic activity of the combination therapy. These findings indicate that co-targeting the mTOR/ERK pathways may provide a suitable precision strategy for HNSCC treatment. Moreover, PIK3CA+ HNSCC are particularly prone to undergo apoptosis after mTOR and ERK inhibition, thereby providing a potential biomarker of predictive value for the selection of patients that may benefit from this combination therapy.
KW - Co-targeting therapy
KW - Rapamycin
KW - Shrna library
KW - Synthetic lethality screen
KW - Trametinib
UR - http://www.scopus.com/inward/record.url?scp=84962003825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962003825&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.7372
DO - 10.18632/oncotarget.7372
M3 - Article
C2 - 26882569
AN - SCOPUS:84962003825
SN - 1949-2553
VL - 7
SP - 10696
EP - 10709
JO - Oncotarget
JF - Oncotarget
IS - 10
ER -